

Capital Increase through Third-Party Allotment**— " Nematode cancer test "N-NOSE" to expand business and enhance services —**

HIROTSU Bio Science Inc. (Head Office: Chiyoda-ku, Tokyo; Representative; Takaaki Hirotsu (Hereinafter referred to as "HIROTSU")), has recently issued new shares through a third-party allotment to several investors including NPH Holdings, Inc. (headquartered in Nada-ku, Kobe-shi, Hyogo; Shigeru Nagate, CEO) and D Data Business Supply Co.,Ltd. (headquartered in Shibuya-ku, Tokyo; Ichiro Togo, CEO).

Since its commercialization in January 2020, the nematode cancer test "N-NOSE" has expanded its services, and the number of examinees has exceeded 500,000. In order to make N-NOSE available to an ever-increasing number of people, we will work to enhance our services by jointly marketing N-NOSE and collecting specimens through the group companies of NPH Holdings, Inc. In addition, we plan to further expand our business with the cooperation of Data Business Supply Co.,Ltd.

■ About NPH Holdings, Inc.

Company Name : NPH Holdings, Inc.
Headquarters : 3-3-11 Eboshicho, Nada-ku, Kobe-shi, Hyogo
Representative : Shigeru Nagate, CEO
Date of Establishment: January 1, 2012
Main Service : Management of business group companies
Official Website : <https://nph-holdings.co.jp/>

■ About Data Business Supply Co.,Ltd.

Company Name : Data Business Supply Co.,Ltd.
Headquarters : Ichigo Nishisando Building annex, 3-28-6 Yoyogi, Shibuya-ku, Tokyo
Representative : Ichiro Togo, CEO
Date of Establishment: September 1, 1976

Main Service : Logistics, call center, manufacturing of printed and promotional materials, sales of systems and barcode solutions

Official Website : <https://www.dbs.jp/>

■ About HIROTSU Bio Science

We as HIROTSU aim to protect the health and future security of people through research, development, and practical application of unique technology that utilize the capabilities of living organisms. Established in 2016, N-NOSE was put into practical use thanks to our researchers' abundance of ideas and tireless efforts. Despite the importance of extending healthy life expectancy being emphasized, it is said that one in every two people will be diagnosed with cancer in this age of 100-year life expectancy. We strive to contribute to solving these social issues with our groundbreaking "bio-diagnoses" technology that utilizes the power of nematodes.

Company Name : HIROTSU Bio Science Inc.

Headquarters : 22F New Otani Garden Court, 4-1 Kioi-cho, Chiyoda-ku, Tokyo

Representative : Takaaki Hirotsu, CEO

Date of Establishment: August 2016

Main Service : Research, development, and marketing of cancer screenings using nematodes and nematode olfactory sensors

Official Website : <https://hbio.jp/en/>

■ About "N-NOSE"

A primary screening test for cancer that utilizes the highly accurate detection of cancer-specific odors in human urine by the nematode *C. elegans*, which has a very good sense of smell. By simply submitting urine, the test is simple, inexpensive, highly accurate, and provides a whole-body comprehensive examination of early-stage cancer risk.

Official Service Website: <https://lp.n-nose.com/>

■ About "N-NOSE plus Pancreas"

N-NOSE's next-generation "Cancer Type Specific Test". This test uses a "special nematode" genetically engineered from the nematode *C. elegans* that specifically reacts only to the smell of pancreatic cancer. This "special nematode" has a high ability to distinguish between

pancreatic cancer and other cancers, enabling non-invasive detection of early-stage pancreatic cancer.

Official Service Website: <https://lp.n-nose.com/suizou/>

■ About “N-NOSE Animals”

“N-NOSE Dogs” and “N-NOSE Cats” developed based on the N-NOSE technology. Up until now, there has not been an easily accessible cancer screening test for pets. Just like N-NOSE for humans, starting in 2023, an easy cancer risk screening only requiring urine for both cats and dogs has been made available due to this product.

Official Service Website: <https://lp.n-nose.com/animal/>

Press Contact

HIROTSU Bio Science PR

E-mail : press@hbio.jp